个人简介

PhD (London), MPhil (Bradford), BSc Hons (Bradford)

研究领域

Characterisation of the reticuloplasmins as anticancer drug targets. Pharmacology of vascular disrupting agents. Development of 3Rs methodologies. Exploitation of the fluorescent properties of anti-cancer therapeutics for utilisation in assessment of pharmacodynamic and pharmacokinetic end-points. Evaluation of the drugability of the tumor cell glycocalyx.

Development of 3Rs methodologies; the mechanics of cell migration; natural products as a source of anti-cancer agents; characterisation of the reticuloplasmins as anticancer drug targets; pharmacology of vascular disrupting agents

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hussain N, Connah D, Ugail H, Cooper PA, Falconer RA, Patterson LH, Shnyder SD (2016). The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models. Scientific Reports (accepted for publication) Ross RL, McPherson HR, Kettlewell L, Shnyder SD, Hurst CD, Alder O, Knowles MA (2016). PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer (accepted for publication) Grant CA, Twigg PC, Saeed RF, Lawson G, Falconer RA, Shnyder SD (2016). The effect of polysialyltransferase modulation on glioma cell nano-mechanics. BioNanoSci 6: 81-84 DOI 10.1007/s12668-016-0192-2 Ayuso JM, Basheer HA, Monge R, Sánchez-álvarez P, Doblaré M, Shnyder SD, Vinader V, Afarinkia K, Fernández LJ, Ochoa I (2015). Study of the chemotactic response of multicellular spheroids in a microfluidic device. PLoS ONE 10: e0139515 Batubara A, Carolan VA, Loadman PM, Sutton C, Shnyder SD, Clench MR (2015). Thin-layer chromatography/matrix-assisted laser desorption/ionisation mass spectrometry and matrix-assisted laser desorption/ionisation mass spectrometry imaging for the analysis of phospholipids in LS174T colorectal adenocarcinoma xenografts treated with the vascular disrupting agent DMXAA. Rapid Commun Mass Spectrom 29: 1-9 Vinader V, Sadiq M, Sutherland M, Huang M, Loadman PM, Elsalem L, Shnyder SD, Cui H, Afarinkia K, Searcey M, Patterson LH, Pors K (2015). Probing cytochrome P450-mediated activation with a truncated azinomycin analogue.Med Chem Comm 6: 187-191 Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro Morais G, Patterson LH, Falconer RA (2014). Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity against Solid Tumors and Reduced Potential for Cardiovascular Toxicity. Mol Pharm 11: 1294-1300 Van Rijt SH, Romero-Canelón I, Fu Y, Shnyder SD, Sadler PJ (2014). Potent organometallic osmium compounds induce mitochondria-mediated apoptosis and S-phase cell cycle arrest in A549 non-small cell lung cancer cells. Metallomics 6:1014-1022 Al-Saraireh YMJ, Sutherland M, Springett BR, Freiberger F, Morais GR, Loadman PM, Errington RJ, Smith PJ, Fukuda M, Gerardy-Schahn R, Patterson LH, Shnyder SD, Falconer RA (2013). Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. PLoS ONE 8: e73366 Sheldrake H, Travica S, Johansson I, Loadman P, Sutherland M, Elsalem L, Illingworth N, Cresswell AJ, Reuillon T, Shnyder SD, Mkrtchian S, Searcey M, Sundberg MI, Patterson LH, Pors K (2013). Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. J Med Chem. 56: 6273-6277 Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, Turner NC (2013). Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3 mutant cancer. Cancer Discov. 3: 1058-1071 Smith PJ, Furon E, Wiltshire M, Chappell S, Patterson LH, Shnyder SD, Falconer RA, Errington RJ (2013). NCAM polysialylation during adherence transitions: Live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7. Cytometry A. 83: 659-671 Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, Alandas MN, Sheldrake HM, Mkrtchian S, Patterson LH, Ingelman-Sundberg M (2013). Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res. 19: 2952-2961 O Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH (2013). Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol. 169: 719-735 Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, Alandas MN, Cooper PA, Searcey M, Pors K, Shnyder SD, Patterson LH (2013). Antitumor activity of a duocarmycin analogue rationalised to be metabolically activated by Cytochrome p450 1a1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 12: 27-37 Cosentino L, Redondo-Horcajo M, Zhao Y, Santos AR, Chowdury KF, Vinader V, Abdallah QM, Abdel-Rahman H, Fournier-Dit-Chabert J, Shnyder SD, Loadman PM, Fang WS, Díaz JF, Barasoain I, Burns PA, Pors K (2012). Synthesis and Biological Evaluation of Colchicine B-Ring Analogues Tethered with Halogenated Benzyl Moieties. J Med Chem. 55: 11062-11066 Fournier-Dit-Chabert J, Vinader V, Santos AR, Redondo-Horcajo M, Dreneau A, Basak R, Cosentino L, Marston G, Abdel-Rahman H, Loadman PM, Shnyder SD, Díaz JF, Barasoain I, Falconer RA, Pors K (2012). Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation. Bioorg Med Chem Lett. 22: 7693-7696 Sutherland M, Gordon A, Shnyder SD, Patterson LH, Sheldrake HM (2012). RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis. Cancers 4: 1106-1145 Falconer, RA, Errington RJ, Shnyder SD, Smith PJ, Patterson LH (2012). Polysialyltransferase: a new target in metastatic cancer. Curr Cancer Drug Targets 12: 925-929 Burns CJ, Fantino E, Powell AK, Shnyder SD, Cooper PA, Nelson S, Christophi C, Malcontenti-Wilson C, Dubljevic V, Harte MF, Joffe M, Phillips ID, Segal D, Wilks AF, Smith GD (2011). The microtubule depolymerising agent CYT997 causes extensive ablation of tumor vasculature in vivo. J Pharmacol Exp Ther 339:799-806